Florida Peptide Research Regulatory Overview
Federal and state regulatory context for research-grade peptide compounds in Florida. Informational summary for scientific researchers and research institutions.
Disclaimer: This page provides general regulatory context for informational purposes only and does not constitute legal advice. Researchers should consult applicable federal and state regulations and qualified legal counsel before making any decisions based on this content.
Federal Regulatory Context
Federal oversight of research chemicals involves FDA regulation of commercial sale and use, and DEA scheduling under the Controlled Substances Act for specific compounds meeting abuse potential criteria. Research-grade peptide compounds including BPC-157, TB-500, GHK-Cu, NAD+, and Epithalon are not currently listed under any federal DEA controlled substance schedule and are therefore available for procurement and use in legitimate in vitro laboratory research without DEA-specific registration requirements applicable to scheduled substances. These compounds must be sold under the Research Use Only designation and used for scientific research purposes.
Florida State Context
Florida Statutes Chapter 893 establishes five controlled substance schedules that generally parallel federal CSA scheduling. The Florida Comprehensive Drug Abuse Prevention and Control Act does not currently include unscheduled research-grade peptide compounds within its scheduling provisions. Florida law additionally governs compounding pharmacies, but research-grade peptide compounds purchased for in vitro laboratory research from research chemical suppliers operate in a different regulatory context than compounded pharmaceutical preparations. Researchers in Florida should seek institutional compliance guidance and qualified legal counsel for situation-specific regulatory assessment.
Research Overview
Florida has a significant biomedical research presence through the University of Florida, University of Miami Miller School of Medicine, Moffitt Cancer Center, Florida State University, and the Max Planck Florida Institute for Neuroscience. Research-grade peptide compounds for in vitro laboratory research are regulated at the federal level under FDA and DEA jurisdiction, with the CSA applying to scheduled substances. Florida state law under Chapter 893 of the Florida Statutes (the Florida Comprehensive Drug Abuse Prevention and Control Act) establishes state controlled substance scheduling, which tracks federal scheduling but does not include the unscheduled research peptide compounds such as BPC-157, TB-500, GHK-Cu, NAD+, and Epithalon. Florida researchers and institutions should operate within appropriate institutional compliance frameworks when procuring research chemicals.
- •University of Florida College of Medicine
- •University of Miami Miller School of Medicine
- •Moffitt Cancer Center
Commonly Researched Compounds
Research-grade compounds commonly procured by institutions in Florida for in vitro and preclinical research programs.
Frequently Asked Questions
Legal Disclaimer
The information on this page is provided for general informational and educational purposes only. It does not constitute legal advice and should not be relied upon as such. Laws and regulations governing research chemicals, peptides, and related compounds vary by jurisdiction and are subject to change. Researchers and organizations should consult a qualified legal professional familiar with federal and state law applicable to their specific situation before making any decisions based on this content. Spartan Peptides does not provide legal counsel and makes no representations regarding the legal status of any compound in any specific jurisdiction.
Explore All Research-Grade Compounds
Browse the full Spartan Peptides research compound catalog. All compounds are research-grade, supplied as lyophilized powder with certificate of analysis, for in vitro laboratory research use only.